Monthly Archives: August 2012

Organovo Reports Q2 2012 Financial Results, Provides Business Update

Posted on by

SAN DIEGO, Aug. 15, 2012 /PRNewswire/ --Organovo Holdings, Inc. (ONVO) ("Organovo") a three-dimensional biology company focused on delivering breakthrough 3-D bioprinting technology, today reported unaudited financial results for the period ended June 30, 2012.

(Logo: http://photos.prnewswire.com/prnh/20120813/MM55537LOGO)

Organovo is focused on breakthrough 3D bioprinting technology to create tissue on demand for research and medical applications. The company's NovoGen MMX Bioprinter() is part of a 3D human tissue generation platform that works across a broad array of tissue and cell types to recapitulate in vivo biology. Organovo's bioprinting technology has immediate applications in disease research, drug discovery and development, and toxicology testing. In the future, the Company believes that applications of this technology hold the promise to generate tissues for therapeutic uses.

Second quarter 2012 revenues increased approximately 49% above the same period in 2011. Collaborative research revenues for the second quarter increased approximately 81% over the same period of prior year revenues, but were partiallyoffset by a reduction in grant revenues. Loss from Operations for the second quarter was approximately $1,449,700.

Recent Corporate HighlightsOn July 17, 2012, Organovo announced the commencement of operations at its new, larger facility in San Diego, California. The new facility has over three times the capacity of Organovo's previous headquarters and is expected to facilitate the Company's needs to grow staff and research and development output.

On July 9, 2012, Organovo announced the receipt of two issued patents. The patents consisted of the issuance in the United States of a patent to which the Company owns the exclusive license from the University of Missouri, and the issuance in the United Kingdom of the Company's first assigned patent.

On July 9, 2012 Organovo announced the appointment of James T. Glover, former CFO of Beckman Coulter and Anadys Pharmaceuticals, to its Board of Directors. Mr. Glover has been affirmed as an independent director by the Organovo Board of Directors, and the Company expects to attract additional independent directors as it grows.

On May 21, 2012, Organovo announced the hiring of Dr. Eric Michael David as Chief Strategy Officer.

On April 25, 2012, Organovo announced the hiring of Michael Renard as its Executive Vice President, Commercial Operations, and the promotion of Dr. Sharon Presnell to Chief Technology Officer.

The Company is performing on current contracts with Pfizer and United Therapeutics. The Company expects to book revenue on both contracts in the second half of 2012.

More:
Organovo Reports Q2 2012 Financial Results, Provides Business Update

Grey's Anatomy(TM) Professional Wear by Barco Signature Series Brings Professional Polish

Posted on by

GARDENA, CA--(Marketwire -08/15/12)- Barco Uniforms, an acclaimed leader in the uniform industry, unveiled its striking new Grey's Anatomy Professional Wear by Barco Signature Series. The collection, with new fabric, colors and designs, builds on the company's most popular styles, adding a professional, "heathered" look and arcLux with stretch, which clothes professionals in luxurious comfort that stretches and flatters every shape and fit.

"Barco Uniforms shares the passion and commitment medical professionals bring to their work every day, and we understand that while their uniforms must be practical, professionals desire comfortable, flattering, professional styles," said David Murphy, Senior Vice President, of Sales and Marketing at Barco Uniforms. "Our new Grey's Anatomy Professional Wear by Barco Signature Series is designed to deliver the ease and performance expected from Barco Uniforms in fashion-forward, sophisticated styles."

The new collection is created from soft, touchable fabrics that stretch to move with the body to deliver professional polish, whether meeting with colleagues, patients or families, handling crises or providing everyday care. Four exciting new colors -- Electric Heather, Punch Heather, Purple Rain Heather and Hot Tamale Heather -- complement Barco's popular Bahama Heather, Black Heather, Cabernet Heather, and Indigo Heather fabulous prints to create the perfect palette for expanding or designing an entirely new wardrobe. Advanced moisture wicking ensures all-day ease, even through the longest and most demanding shifts.

Grey's Anatomy Professional Wear by Barco Signature Series is available now at leading medical uniform retailers. To locate a retail outlet, visit http://medical.barcouniforms.com/medical/locator.asp.

About Barco UniformsBarco Uniforms, a recognized leader in the uniform industry, fuses innovative fabric technology and fashion-forward design to create uniforms that inspire individuals and enhance the work environment. From its versatile, widely appealing Medical Collections and distinctive Spa Collection, to its corporate Identity solutions, Barco Uniforms is committed to making professional attire that people love to wear. For more information, visit http://www.barcouniforms.com/.

Excerpt from:
Grey's Anatomy(TM) Professional Wear by Barco Signature Series Brings Professional Polish

ChemAxon Announces New Version of chemicalize.org for Tablet PCs

Posted on by

BUDAPEST, Hungary, August 14, 2012 /PRNewswire/ --

ChemAxon, a leader in providing chemistry software for the biotechnology and pharmaceutical industries, announces that its free, open access, web-based chemistry search and extraction service, chemicalize.org, is now supported on touchscreen tablet PCs including Apple iPad and Android devices. This new version provides users with high resolution chemically-intelligent web search and extraction on the move.

Powered by ChemAxon technology and used by scientists worldwide, chemicalize.org identifies chemical names (SMILES, InChI, traditional and IUPAC names) on websites, in text and PDF files, converting them to 2D structures. Researchers can also calculate and explore a range of structure-based properties, search by structure in the ever expanding chemicalize.org knowledge-base, and search the internet to find all websites citing a particular chemical structure.

The new chemicalize.org features:

To try for yourself visit http://www.chemicalize.org

To discover more about how ChemAxon's leading edge cross platform solutions power modern cheminformatics and chemical communication, please visit http://www.chemaxon.com

About ChemAxon

ChemAxon is a leader in providing cheminformatics software development platforms and desktop applications for the biotechnology, pharmaceutical and agrochemical industries. With core capabilities for structure visualization, search and management, property prediction, virtual synthesis, screening and drug design, ChemAxon focuses upon active interaction with users and software portability to create powerful, cost effective cross platform solutions and programming interfaces to power modern cheminformatics and chemical communication. The company is privately owned with European headquarters in Budapest and sales and support offices in Europe, Japan and North America.

The ChemAxon logo is a trademark of ChemAxon Ltd. All rights reserved. All other trademarks mentioned in this document are the property of their respective owners.

Original post:
ChemAxon Announces New Version of chemicalize.org for Tablet PCs

Primary looks to strong earnings growth

Posted on by

Medical centres operator and pathology provider Primary Health Care has unveiled a near 50 per cent rise in full year profit and forecast stronger earnings in 2012/12.

Primary lifted its net profit for the year to June 30 by 49 per cent to $116.6 million, from $78.3 million in 2010/11.

Revenue climbed 5.3 per cent to $1.4 billion.

Primary impressed investors by forecasting a 20-25 per cent rise in earnings per share (EPS) in 2012/13.

Its EPS was 23.3 cents a share in 2011/12.

Primary also expects earnings before interest, tax, depreciation and amortisation to climb to $370-380 million in 2012/13, from $351.1 million in 2011/12.

"Primary is able to look forward to strong growth as a result of the underlying strength of the business, positive industry dynamics, and long-term increasing demand for healthcare services," Primary said in a statement on Wednesday.

Shares in the company were 34 cents, or 11 per cent, higher at $3.43 at 1038 AEST.

Primary, which operates 76 medical centres, said it expected consolidation in the industry to continue and would look for small bolt-on acquisitions.

Its medical centres, pathology and medical imaging divisions all lifted their earnings and revenue during 2011/12.

Read the original post:
Primary looks to strong earnings growth

New method to closely model diseases caused by splicing defects

Posted on by

ScienceDaily (Aug. 14, 2012) A team led by scientists at Cold Spring Harbor Laboratory (CSHL) has developed a new way of making animal models for a broad class of human genetic diseases -- those with pathology caused by errors in the splicing of RNA messages copied from genes. To date, about 6,000 such RNA "editing" errors have been found in various human illnesses, ranging from neurodegenerative disorders to cancer.

The new modeling approach can provide unique insights into how certain diseases progress and is likely to boost efforts to develop novel treatments. It was tested successfully by the CSHL team, led by Professor Adrian Krainer, Ph.D., in collaboration with scientists from Isis Pharmaceuticals, in mouse analogs of human spinal muscular atrophy (SMA), a motor-neuron disease that is the leading genetic cause of childhood mortality. The results are detailed in a study published August 15 in Genes & Development.

The modeling method is called TSUNAMI (shorthand for targeting-splicing using negative ASOs to model illness). The study demonstrates it can be used in illnesses with pathology associated with the missplicing of pre-mRNAs -- unedited RNA molecules that bear the messages encoded in genes which provide instructions for cells to manufacture specific proteins.

Correcting splicing errors in SMA

A cellular machine called the spliceosome routinely snips non-essential bits called "introns" out of every pre-mRNA molecule that carries a copy of a gene's instructions. All that should remain after the spliceosome has done its work is a string of spliced-together "exons," the protein-encoding portions of the message. These edited mRNA messages are subsequently read by ribosomes, the cellular factories where proteins are synthesized.

In SMA and some other human illnesses, pathology can be traced to errors in the pre-mRNA editing process. In SMA, it is caused either by a severe mutation in a gene called SMN1 ("survival of motor neuron-1") or by that gene's complete absence in an affected individual's genetic material. The SMN protein normally encoded by the gene is essential for motor neuron development. Humans have a second, similar gene called SMN2, but it is a poor backup. Because of an error in the splicing of its pre-mRNA, the SMN2 gene, when expressed, typically produces only a fraction of the SMN protein needed by motor neurons. This is critical in the first stages of life when the body and muscles are still developing.

While the level of the "backup" gene's protein output varies in individuals with spinal muscular atrophy, resulting in pathology of varying intensity, Krainer -- a leading expert on splicing -- and his collaborators have succeeded in recent years in devising a method of getting SMN2 to produce therapeutic amounts of protein, enough to reverse pathology in both mild and severe mouse analogs of the disorder.

To achieve this they synthesized tiny snippets of RNA called ASOs (antisense oligonucleotides) and injected them into the cerebrospinal fluid of mice carrying a human SMN2 transgene (i.e., a gene not native to mice). This enabled them to get the therapeutic ASOs through the so-called blood-brain barrier, to reach cells throughout the central nervous system. ASOs are configured to attach at highly specific spots in pre-mRNAs, where, by design, they can inhibit activators or repressors of the splicing process. Krainer's team synthesized an ASO that corrected the SMN2 splicing error and gave rise to therapeutic amounts of SMN protein. Importantly, the ASO was shown to be stable in the body as well as persistent, the effects of a single injection lasting at least half a year in mice.

TSUNAMI's 'negative ASOs': therapy in reverse

A version of this therapeutic ASO is now being tested in Phase 1 human trials. But even as the tests proceed, Krainer and colleagues have worked on getting the splice-correction method to work in reverse: using a "negative ASO" to cause or exacerbate disease pathology in neonatal mice, with the approach they call TSUNAMI.

Read more:
New method to closely model diseases caused by splicing defects

Starkville nutrition store owner helps clients find their 'want to'

Posted on by

Chris Williams, owner of Peak Nutrition, originally planned to enter law school or pursue a career in politics but his own struggle with weight led him to open his own nutrition store in Starkville. Photo by: Micah Green/Dispatch staff

If you had asked Chris Williams where he thought he would be at 23 years old, he probably would have told you he would be in law school or working in the political arena. Instead, the former football player turned entrepreneur has opened his own nutritional shop in Starkville.

Truly one of a kind to the area, Peak Nutrition focuses on the body and the mind. Williams opened the store last week and said he already has customers lining up to try the shakes made in house and the meal plans targeted to athletes on the go.

Williams said that before anyone can begin to get in shape, they first must have the desire or as he commonly calls it, "the want to."

He said he had that break through moment several months back. Williams played football all throughout high school and college, first as a tight end and then as a defensive tackle. Williams said he quickly gained weight when playing, starting out at less than 220 pounds and to 278 pounds by his senior year. When he graduated from Mississippi College in December 2011, he quit playing football, but kept consuming the same amount of calories as when he was working out on the field. Williams said he knew he needed to lose weight but didn't know where to start. Not only was he becoming unhappy with his weight, Williams was also beginning to question the direction his professional life was going as well. That is when he said he had that "want to" moment and approached a friend to help him lose weight. Williams began eating right and leading an active lifestyle, focusing not only on his physical health, but his mental health as well. He quickly began losing weight but in addition, his state of mind changed, too. He said he had more energy and was on overall happier person.

Link:
Starkville nutrition store owner helps clients find their 'want to'

Complete Nutrition Names Sheldon Harris Chief Executive Officer

Posted on by

OMAHA, Neb., Aug. 14, 2012 (GLOBE NEWSWIRE) -- Sheldon Harris, the former president of the ice cream franchise Cold Stone Creamery, has been named Complete Nutrition's CEO, effective immediately. Former CEO Cory Wiedel, who founded the company in 2005, will serve as Chairman of the newly created board of directors.

Harris has been involved with Complete Nutrition for the past six months, leading the development team as a consultant. In this role, he strategically outlined a road map for growth as Complete Nutrition continues to increase its national footprint, with plans to add 150 new stores in the next three years. In the past few years, the company has gone from a 15-store regional chain to a 160-unit national brand.

"Sheldon is an exceptional leader who brings impressive experience in franchising and working with high-growth companies to Complete Nutrition," said Wiedel. "After growing at an unprecedented rate for the past three years, our priority has been to assemble a top-notch executive team. Naming Sheldon as CEO of Complete Nutrition fulfills this objective."

Earlier in his career, Harris served as president of Cold Stone Creamery from 1996-2006. The franchise catapulted from a handful of stores to more than 1,400 international and domestic locations during his tenure. Harris' crowning moment at Cold Stone Creamery came in 2006 when the franchise was named No. 11 in Entrepreneur magazine's list of fastest-growing franchises.

"I'm thrilled to join the Complete Nutrition team," said Harris. "As a health and fitness enthusiast, it's an honor to be in a position where I can help people make dramatic, positive life changes through our consultative approach and superior products."

Other notable milestones in Harris' career include overseeing operations in Alaska for wholesale giant Costco where he was responsible for managing 350 employees and $160 million in sales. In 2006, Harris launched Trust Funding, a consumer-lending company, which to date has helped more than 3,000 people who have faced hardships reach financial solvency.

Complete Nutrition offers more than 200 exclusive general health, sports nutrition and weight-loss supplements. Employing certified personal trainers, former strength coaches and others experienced in health and fitness, Complete Nutrition differentiates itself from competitors through its consultative approach to nutritional supplements.

About Complete Nutrition

Complete Nutrition is a network of high quality nutritional supplement retail stores whose mission is to create a safe and effective weight management, sports nutrition, and healthy aging program to help customers look better, feel better, and perform better. Since 2005, Complete Nutrition has been helping people achieve their health and wellness goals by offering exclusive supplements at affordable prices. Staff members are athletes, certified personal trainers, nutritionists, and other people with experience in the health and fitness supplement retail industry. CEO Cory Wiedel and President Ryan Zink were named finalists of the Ernst & Young Entrepreneur Of The Year(R) 2012 Central Midwest award. Complete Nutrition recently earned the following top honors from Entrepreneur Magazine in 2012: Franchise 500 award recipient, No. 2 Top New Franchise, No. 36 Fastest-Growing Franchise. Additionally, Complete Nutrition was named to the 2011 Allbusiness.com AllStar Franchises Top 300 list. For more information about Complete Nutrition, call 866-366-5766 or visit http://www.CompleteNutrition.com.

The Complete Nutrition logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=12982

Read more:
Complete Nutrition Names Sheldon Harris Chief Executive Officer

DNA doesn’t help inmate prove his innocence

Posted on by

DALLAS -

A Dallas man accused of a rape decades ago has been cleared by DNA twice. But so far he has yet to be exonerated.

Family members have been protesting outside the Lew Sterrett Justice Center on behalf of Ocie Moore.

"He has served 21 years of a 99-year sentence, almost died twice for a crime he did not commit. Now they want to send an innocent man back to prison for a crime he did not commit," said Audra Woods, Moore's sister.

In 1990 Moore and another man were convicted of rape. Since then he has maintained his innocence, even requesting to be DNA tested.

"I passed a DNA test in June. She come back and said they want to do another test. They tested again in April. I passed that one also," Moore said.

Moore's DNA did indeed exclude him. But in this case the allegations involved two men who raped the woman and only one DNA profile could be identified as belonging to the man convicted with Moore.

Prosecutor Russell Wilson said DNA alone does not open the door to freedom. Context matters as much as the content.

"We consider all the information that we can gather -- the scientific test, the testimony at the trial, the witness statements that we're able to gather, his own statements," he said.

Dallas County leads the nation in exonerations. Thirty wrongly-convicted men have been set free, almost all cleared by DNA. But the district attorney's office believes this is one conviction from the early 90s that's right.

See the rest here:
DNA doesn’t help inmate prove his innocence

Posted in DNA

Applied DNA Sciences Reports Fiscal Third Quarter 2012 Results

Posted on by

STONY BROOK, NY--(Marketwire -08/14/12)- Applied DNA Sciences, Inc. (APDN), (Twitter: @APDN), a provider of DNA-based anti-counterfeiting technology and product authentication solutions, announced its financial results for the third fiscal quarter ending June 30, 2012, generating revenues of $528,574. This represents the company's highest recorded quarterly revenues, and is the third sequential quarter to set this record.

Third Quarter Highlights:

"The Company continues to improve quarter over quarter, beginning FY '12 with an exciting first quarter and improving on that performance with each quarter to date," said Dr. James A. Hayward, President and CEO of Applied DNA Sciences. "The continued expansion of our customer base and product offerings have sustained that momentum and contributed to the steady increase in our revenues. The first nine months of fiscal 2012 have been very productive for the Company, so much so that, as we recently announced, we have hired an additional 9 employees and expanded our physical footprint by over 50% in the past twelve months."

Dr. Hayward commented further, "We are pleased with the ongoing success of our partnerships, expanding the breadth and depth of our product offerings with such customers as Martin Guitar (see http://www.adnas.com/newsroom/press_releases). Our relationships continue to flourish and grow as we add new partners and customers. We continue to grow our revenues while managing our expenses closely."

Revenues in the quarter ending June 30, 2012 totaled $528,574 compared to $229,710 for the third quarter ending June 30, 2011, an increase of 130%. The increase in revenues was substantially generated from sales of our SigNature DNA and BioMaterial GenoTyping, our principal anti-counterfeiting and product authentication solutions.

An aggregate of 59% of our revenues was earned from two customers for the current quarter, while one customer accounted for 46% of the Company's total revenues for the nine months ending June 30, 2012.

Selling, general and administrative expenses increased from $1,580,788 for the three months ended June 30, 2011 to $1,752,501 for the three months ended June 30, 2012. The increase of $171,713, represents an 11% increase over the same quarter in the prior fiscal year and is primarily attributable to the cost of stock-based compensation incurred in the current period compared to the same period last year

Net loss dropped $725,350 or 34% for the quarter as compared to the quarter ending June 30, 2011. Loss in the three months ended June 30, 2012 decreased to $1,429,645 from a net loss of $2,154,995 for the three months ended June 30, 2011.

The Company incurred research and development expenses of $99,958 and $47,988 for the three-month periods ended June 30, 2012 and 2011, respectively, and $274,528 and $161,645 for the nine month periods ended June 30, 2012 and 2011, respectively. The increase is attributable to additional research and development activity needed to support current operations.

Total operating expenses increased to $1,955,797 for the three months ended June 30, 2012 from $1,720,668 for the three months ended June 30, 2011, an increase of $235,129 quarter over quarter, or 14%.

Visit link:
Applied DNA Sciences Reports Fiscal Third Quarter 2012 Results

Posted in DNA

Open Journal System web site for Gravitational and Space Biology is Active

Posted on by

Dear Colleagues:

The Open Journal System web site for Gravitational and Space Biology is active, and we continue to encourage manuscript submissions of all kinds. The instructions to authors can be found on the website, and in the front-matter of the September 2011 issue.

Manuscripts can be submitted any time through the website, http://GravitationalAndSpaceBiology.org, and will be published in the order of their completion through the peer review and author revision process. Manuscripts for the Fall 2012 issue are in various stages of the submission and review, However, depending on the time it takes to navigate the peer review system, manuscripts submitted as late as August 31st can still make it into the Fall issue. So please do not hesitate if you have a paper of interest you would like to submit!

Submission is open to all (members and non-members alike), and we are actively encouraging papers in the fields of gravitational and space biology, astrobiology, analog environment research, advanced life support (ALS), as well as biophysics, radiation biology, engineering, and hardware development relevant to these arenas. The categories of papers include Short Communication, Methods, Research, and Review. In addition, we are also opening a new category: Hypothesis. Guidelines for each category can be found in the Instructions to Authors, and you may feel free to contact any of the members of the Editorial team for guidance at any time.

The value of the journal to ASGSR, and to the scientific community, depends heavily on the quality and number of articles submitted. We look forward to receiving many high-quality papers that strongly reflect the exciting research of our members. We are the face of ASGSR.

As always, do not hesitate to e-mail with any questions, concerns, or suggestions.

Best regards, Anna-Lisa Paul alp - at - ufl.edu

Editor, Gravitational and Space Biology

Please follow SpaceRef on Twitter and Like us on Facebook.

View original post here:
Open Journal System web site for Gravitational and Space Biology is Active

NIH backs Rice University study of delay in gene transcription networks

Posted on by

Public release date: 14-Aug-2012 [ | E-mail | Share ]

Contact: David Ruth david@rice.edu 713-348-6327 Rice University

A Rice University researcher and his colleagues have received a National Institutes of Health grant to see how delays in gene transcription life's most basic messaging system affect cellular processes.

Matthew Bennett, an assistant professor of biochemistry and cell biology, will receive more than a million dollars over five years to gather and combine data from computer simulations and live cells. The goal is to create techniques to generate and analyze models of gene networks that incorporate delay as part of their process.

"Delay in transcriptional signaling is an unavoidable consequence of the way biochemistry works," said Bennett, a theoretical physicist by training who turned to synthetic biology as a postdoctoral researcher before joining Rice in 2009. "Once a gene is activated, often as a response to a molecule being introduced into the cell, it takes time for the results to come to fruition. Eventually the DNA must be transcribed into RNA, and the RNA must be translated into protein. Then, sometimes, the protein has to be modified or has to fold."

Bennett and his team want to know precisely what happens and why in that cascade of events, which can take minutes. "We want to be able to create accurate mathematical models of gene networks in order to predict how they function and how they fail, so we can design new synthetic networks and know what they're going to do before we build them," he said.

Synthetic biology has become an increasingly hot topic as researchers create biological systems not found in nature. (A leader in the field, J. Craig Venter, will speak at Rice on Oct. 10 as part of the university's Centennial Celebration.)

Bennett sees the process as similar to sophisticated electronic design, in which the genetic equivalent of logic gates can be used to program circuit-like behavior in living things. The resulting genomes can be used in cells for information processing, materials fabrication, chemical sensing, the production of energy and even food.

"We've learned that delays can have a significant impact on the function of genetic networks, and the discoveries have changed our fundamental understanding of how genes talk to one another," Bennett said. "There are many processes in cells that require specific timing in order to operate: Stress responses, circadian oscillations, cellular growth and division. We've found the dynamics of these networks are important to their function, and delay can have a profound effect. Understanding that delay and being able to model is critical for accurate computational simulations."

While simple models are able to help build simple cellular "circuits," Bennett felt a more sophisticated model will expand the possibilities for synthetic biology and lower the cost of engineering new synthetic microbes.

View post:
NIH backs Rice University study of delay in gene transcription networks

AIDP announces it has been granted U.S. patents for Magtein™

Posted on by

CITY OF INDUSTRY, Calif., Aug. 14, 2012 /PRNewswire/ -- AIDP, Inc., the distributors of Magtein magnesium L-threonate, expected to be the next breakthrough ingredient for cognitive health, has been awarded two patents for magnesium compositions and uses for cognitive function (Patent 8,178,118) and neurological disorders (Patent 8,142,803).

(Logo: http://photos.prnewswire.com/prnh/20120814/SF56977LOGO)

The patents, titled "Magnesium compositions and uses thereof for cognitive function" (Patent 8,178,118) and "Magnesium compositions and uses thereof for neurological disorders" (Patent 8,142,803) are among the four U.S. patents awarded from seven ongoing patent applications, including international rights. These patents protect Magtein's unique magnesium compositions and its use for any magnesium L-threonate-containing food, nutritional supplements and drugs for enhancing cognitive function or ameliorating the effects of a neurological disorder. The use of these products is applicable for improving the health of people suffering from loss of cognitive function, loss of memory, Alzheimer's disease, depression, attention deficit hyperactivity disorder, Amyotrophic lateral sclerosis (ALS), Parkinson's disease, migraine, anxiety disorder, and mood disorder, as some representative of cognitive and neurological disorders.

"We truly believe that Magtein is a game changing ingredient that will benefit millions of busy and stressed consumers by helping to improve their quality of life," says Edward Lee Ph.D., AIDP president.

"AIDP, as the exclusive provider of all Magtein magnesium L-threonate, is uniquely positioned to serve the functional food and beverage marketplace to support the cognitive health category," added Dr. Lee.

Discovered byGuosong Liu, M.D., Ph.D., and a group of scientists at Massachusetts Institute of Technology (MIT), and Tsinghua University in Beijing, China, studies on Magtein have been published in prestigious journals of neuroscience Neuron (January 2010) and The Journal of Neuroscience (October 2011). With cognitive diseases the seventh leading cause of death in the U.S. and growing at an alarming rate, Magtein, which has self-affirmed GRAS status, is the only form of magnesium proven to significantly increase brain magnesium levels. Furthermore, animal research showed Magtein improved short-term and long-term memory as well as spatial recognition.

Dr. Liu is the president and founder of the Center for Learning and Memory, School of Medicine, Tsinghua University, Beijing, China and Adjunct Full Professor of the Center for Learning and Memory, University of Texas Austin. Dr. Liu is an investigator at the Picower Institute for Learning and Memory and is a former professor at the department of brain and cognitive science and the department of biology at MIT.

For over 15 years, AIDP, Inc. based in City of Industry, CA, has been a leader in functional ingredients for a wide-range of applications from vitamins, minerals and amino acids, to specialty and proprietary products. Pioneering breakthroughs for the research and development of proprietary ingredients for bone, joint and cognitive health under the anti-aging platform, the AIDP mission is to achieve ultimate customer satisfaction through creative product innovation and superior service.

For more information about Magtein magnesium L-threonate studies, call Kathy Lund, AIDP vice president of business development and marketing, at 303.734.0860 or visit http://www.AIDP.com.

Follow this link:
AIDP announces it has been granted U.S. patents for Magtein™

The new face-lifting acupuncture treatment that claims to take five years off (but could you handle the needles?)

Posted on by

By Daily Mail Reporter

PUBLISHED: 16:27 EST, 14 August 2012 | UPDATED: 16:27 EST, 14 August 2012

A non-surgical alternative to Botox and cosmetic surgery is fast becoming the new trend for anti-aging procedures.

AcuFacial, a process that involves strategically placing tiny needles on the body and face, has doctors claiming patients can come away looking five to ten years younger.

Shellie Goldstein, a New York acupuncturist, told Good Morning America: 'We are taking your face to the gym, were exercising it. We have muscles in our body, we have muscles in our face, there is no other procedure that actually exercises the muscles and improves circulation in your skin.'

AcuFacial: A non-surgical alternative to botox and cosmetic surgery fast becoming the new trend for anti-aging

Despite the procedure's lack of scientific backing, people are still choosing the process, which costs $150-$200 per session, with results being seen after ten sessions.

While the results of cosmetic surgery can be unnatural, AcuFacial claims to give men and women a similar outcome without having to pull the skin or put anything underneath.

'We're working with your energy. The energy of your body, to lift it up, to work with the muscles of your face, reduce fine lines and wrinkles, improve muscle tone and give it a beautiful overall glow and complexion,' Ms Goldstein said.

Continued here:
The new face-lifting acupuncture treatment that claims to take five years off (but could you handle the needles?)

Proteonomix Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial with UMK-121 in Patients with …

Posted on by

MOUNTAINSIDE, N.J.--(BUSINESS WIRE)--

Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121. The Proteonomix-sponsored trial will evaluate UMK-121 in patients with end-stage liver disease (ESLD).

Permission by the FDA marks an important milestone in our plans to initiate a Company-sponsored clinical trial with UMK-121, following years of research and investment to advance development of this drug candidate, said Proteonomix Chief Technology Officer Steven Byle. We hope and anticipate that this trial will demonstrate the potential of UMK-121 to mobilize stem cells in order to improve liver function in patients with ESLD. We consider ourselves fortunate to be involved with a development-stage therapy that could improve the life expectancy for this class of terminally ill patients awaiting liver transplants.

Proteonomix CEO Michael Cohen added, This is a significant step for our Company as this is the first FDA IND to be held by Proteonomix and demonstrates the ability of the Company to move basic research projects into clinical trials.

UMK-121 is a patent-pending combination of two FDA-approved drugs designed to mobilize mesenchymal stem cells from the bone marrow to the peripheral circulation. The combination drug is designed to reduce inflammation and increase angiogenesis to restore liver function. UMK-121 was developed by Proteonomix Chief Scientific Officer Ian McNiece and President and CEO Michael Cohen, and subsequently licensed to Proteonomix through its wholly owned subsidiary Thor Biopharma, Inc.

About Proteonomix, Inc.

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. The Proteonomix family of companies includes Proteoderm, StromaCel, PRTMI and THOR Biopharma. Proteoderm is a wholly owned subsidiary that has developed an anti-aging line of skin care products. StromaCel develops therapeutic modalities for the treatment of cardiovascular disease and plans to file an IND application for treatment of patients who have suffered post-myocardial infarction. Proteonomix Regenerative Translational Medicine Institute, Inc. (PRTMI) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Additional information is available at http://www.proteonomix.com and http://www.proteoderm.com.

Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made.

See the original post:
Proteonomix Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial with UMK-121 in Patients with ...

Anatomy of a movie

Posted on by

Readmore: Local, Education, Community, Anatomy of a Murder, Anatomy 59, Iron Industry Museum, Negaunee, James Stewart, Baraga

NEGAUNEE -- The Tuesday lecture series at the Iron Industry Museum in Negaunee continues with a look at Anatomy '59. It's a film made by local journalist John Pepin that takes a behind the scenes look at the movie Anatomy of a Murder. Pepin made the film to celebrate the 50th anniversary of the film. It includes a look at the actual events that led to the book and movie.

"It's a big part of U.P. history because more than 50 years later its still remains a very popular topic with people and a lot of people don't know about the history of the area and how there was a true crime and this actually fits the three together," said Filmmaker John Pepin.

The Tuesday lecture series wraps up at the Iron Industry Museum next Tuesday with a look at the film Iron Spirits: Life on the Michigan Iron Range.

View original post here:
Anatomy of a movie

Two Space Station Spacewalks to be Broadcast on NASA TV

Posted on by

WASHINGTON -- Astronauts and cosmonauts will perform two spacewalks outside the International Space Station this month. NASA Television will broadcast both events live. Coverage of the first will begin at 10 a.m. EDT, Monday, Aug. 20. Coverage of the second will begin at 7 a.m., Thursday, Aug. 30.

The first spacewalk, scheduled to begin at 10:40 a.m., Aug. 20, will feature Expedition 32 Commander Gennady Padalka and Flight Engineer Yuri Malenchenko of the Russian Federal Space Agency in Russian Orlan spacesuits. They will float outside the Pirs docking compartment airlock for a 6 1/2 hour spacewalk to relocate a cargo boom from Pirs to the Zarya module, complete the installation of micrometeoroid debris shields on the Zvezda service module and deploy a small science satellite.

The second spacewalk, scheduled to begin at 8:15 a.m., Aug. 30, will feature NASA Flight Engineer Sunita Williams and Japan Aerospace Exploration Agency Flight Engineer Akihiko Hoshide. The duo will don U.S. extravehicular mobility unit spacesuits for the first U.S.-based spacewalk since July 2011. It will be a 6 1/2 hour excursion designed to replace a faulty power relay unit on the station's truss, rig power cables for the arrival late next year of a Russian laboratory module, and install a thermal cover on a docking port.

The spacewalks will be the 163rd and 164th in support of space station assembly and maintenance. Padalka has conducted eight previous spacewalks and will wear a suit bearing red stripes. Malenchenko has conducted four spacewalks and will wear blue stripes. For the U.S. spacewalk, Williams will wear a suit with red stripes for the fifth spacewalk in her career. Hoshide, wearing a suit with no stripes, will be conducting his first spacewalk. He is the third Japanese astronaut in history to conduct a spacewalk.

International news media planning to cover the U.S. spacewalk in-person at NASA's Johnson Space Center in Houston must apply for accreditation by contacting the Johnson newsroom at 281-483-5111 by 6 p.m., Aug. 21. U.S. media also may begin their application process at this time. International accreditation for the first spacewalk has closed.

For NASA TV streaming video, schedule and downlink information, visit: http://www.nasa.gov/ntv

For more information about the International Space Station and its crew, visit: http://www.nasa.gov/station

Please follow SpaceRef on Twitter and Like us on Facebook.

More here:

Two Space Station Spacewalks to be Broadcast on NASA TV

ISS crew gears up for two space walks

Posted on by

Astronauts living on the International Space Station will cap a busy summer with a pair of spacewalks this month to upgrade and repair the exterior of their home in orbit.

On Monday, two Russian cosmonauts, Gennady Padalka and Yuri Malenchenko, will venture outside the space station to perform a variety of maintenance tasks. Ten days later, on Aug. 30, American astronaut Sunita Williams and Japanese astronaut Akihiko Hoshide will also step out into the vacuum of space to complete their own list of tasks.

The two spacewalks are the only ones planned during the station's current Expedition 32 mission, NASA officials said. Williams and Hoshide will also be performing the first NASA spacewalk in more than a year. The last American excursion outside the orbiting complex was carried out by station astronauts Mike Fossum and Ron Garan in July 2011, during the agency's final space shuttle mission.

"Things are going extremely well on the space station," Dina Contella, Expedition 32 lead flight director at the Johnson Space Center in Houston, told reporters during a news briefing Tuesday. "The crew is in great spirits, looking forward to a pair of spacewalks coming up."

The Russian spacewalk is scheduled to last about 6.5 hours, beginning at 10:40 a.m. EDT.

The cosmonauts will install debris shields to protect parts of the Russian Zvezda service module, and will move a cargo crane from the Pirs docking module to the nearby Zarya module. The crane is being moved to make way for a new Russian laboratory unit that is scheduled to launch to space station and be installed in 2013, NASA officials said. [ Gallery: Building the International Space Station ]

If the cosmonauts complete their main tasks ahead of schedule, they will retrieve two science experiments from the exterior of the station, and release a spherical satellite part of a separate Russian experiment into space.

Padalka and Malenchenko are both veteran spacewalkers. Padalka has conducted eight spacewalks six at the International Space Station and two at the Russian Mir space station. Malenchenko has previously worked outside in the vacuum of space four times.

On Aug. 30, Williams and Hoshide will don their bulky white spacesuits and will embark on a 6.5-hour spacewalk of their own. Williams has conducted four previous spacewalks, but it will be Hoshide's first time venturing outside the orbiting lab, NASA officials said.

The NASA spacewalk, or Extravehicular Activity (EVA), is scheduled to begin at 8:15 a.m. EDT on Aug. 30.

Read more:

ISS crew gears up for two space walks

Space Triathlon: Station Astronaut to Compete Where No One Has Before

Posted on by

As if holding the record for the longest spaceflight by a female astronaut wasn't enough, NASA astronaut Sunita Williams is preparing to compete in a triathlon in space.

Williams, who is stationed aboard the International Space Station, is planning to participate in the 26th annual Nautica Malibu Triathlon in September. But unlike the more than 5,000 athletes who will gather at Zuma Beach in California to swim, bike and run, Williams will compete while orbiting more than 240 miles (386 kilometers) above Earth. She left Earth July 17 for her second long-duration stay in the orbiting lab.

Williams will participate in the Nautica Malibu Triathlon in concert with CNN's chief medical correspondent, Sanjay Gupta, for a CNN special. While Gupta sticks to a more Earthbound experience of swimming in the Pacific Ocean, bicycling and racing through the streets of Malibu, Williams will run, pedal, and engage in a series of bench presses that will serve as the microgravity equivalent of swimming.

As part of her triathlon training, Williams participated from space in the Aug. 12 Falmouth Road Race, an annual seven-mile race from Woods Hole in the town of Falmouth, Mass. [Video: Astronaut to Run Triathlon in Space]

Now she has roughly a month to prepare for the triathlon, which requires competitors to swim half a mile in the ocean, bike 18 miles and run four miles.

Astronauts on long-duration missions at the orbiting outpost exercise roughly two hours each day to combat loss of bone and muscle density. The space station is equipped with a specially designed stationary bike, treadmill (complete with harnesses to keep participants from floating away) and a machine called the Advanced Resistive Exercise Device, or ARED, which acts as a weightlifting machine.

In recent interviews with CNN and WCIA radio in Illinois, Williams described the progress of her training in space, and how her body is adjusting to exercise in the microgravity environment.

"Microgravity is nice to your body," Williams told WCIA. "You can float around, it feels good, but when you simulate gravity when you're on either the treadmill or the ARED it sort of hurts. So it's been a bit of an adjustment to get into the exercise."

During her first two weeks in space, Williams spent time familiarizing herself with the machines, which are either new or have been upgraded since she was last at the space station in 2007.

"The first two weeks we've sort of used as a just-get-used-to-the-equipment, get used to the protocols that we're doing," Williams said at the time. "So I think we're at that point that we're finally adapted and ready to start building on it. So, just watch out, because now I'm ready to really start preparing for the triathlon."

Follow this link:

Space Triathlon: Station Astronaut to Compete Where No One Has Before

NASA Technology Transfer Opportunity: Decorated Carbon Nanotubes for Novel Materials With Tailorable Electrical …

Posted on by

Synopsis - Aug 14, 2012

General Information

Solicitation Number: TTO1025 Posted Date: Aug 14, 2012 FedBizOpps Posted Date: Aug 14, 2012 Recovery and Reinvestment Act Action: No Original Response Date: Dec 31, 2012 Current Response Date: Dec 31, 2012 Classification Code: 99 -- Miscellaneous NAICS Code: 927110 Set-Aside Code:

Contracting Office Address

NASA/Langley Research Center, Mail Stop 12, Industry Assistance Office, Hampton, VA 23681-0001

Description

NASA Langley Research Center in Hampton, VA solicits interest from companies interested in obtaining license rights to commercialize, manufacture and market the following technology. License rights may be issued on an exclusive or nonexclusive basis and may include specific fields of use.

THE TECHNOLOGY:

NASA Langley has created a new class of materials based on depositing nanometer-sized metal particles onto carbon allotropes. The method is scalable and relatively simple, and allows for control over the size and distribution of the metal particles in the substrate, adjusting the surface area to optimize specific thermal or electrical properties of the material. One promising nanocomposite material created consists of multi-walled carbon nanotubes (MWCNTs) decorated with metal particles dispersed in a polymer matrix. Ribbons, tubes, and moldings of the nanocomposite were found to have novel intrinsic electrical characteristics that enable tunable dielectric constants with low loss factors. The decoupling and independent control of the two fundamental parameters offer a class of materials with the potential for finely tailored electronic properties. The novel methods enable materials that show promise for a variety of applications in electronics, communications, catalysis, and optics.

To express interest in this opportunity, please respond to Sean Sullivan, Research Triangle International (RTI), at: NASA Langley Research Center, 17 West Taylor St., Mail Stop 218, Building 1212, Room 110 Hampton, Virginia, E-mail: Sean.D.Sullivan@NASA.gov, or phone: 757-864-5055. Please indicate the date and title of the FBO notice and include your company and contact information. For more information about licensing other NASA-developed technologies, please visit the NASA Technology Transfer Portal at http://technology.nasa.gov/ .

Visit link:

NASA Technology Transfer Opportunity: Decorated Carbon Nanotubes for Novel Materials With Tailorable Electrical ...